CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,001 enrolled
Drug / intervention
aspirin +1 moredrug
Likely dose
aspirin 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00222261
NCT00222261Phase 4Completed

Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.

Ullevaal University Hospital·interventional·Posted Sep 22, 2005·Updated Mar 23, 2011

In Brief

A Phase 4 clinical trial evaluating aspirin and clopidogrel for Coronary Heart Disease and 2 related conditions. Completed, enrolled 1,001 participants across 1 site.

Detailed Summary

In the ASCET study, 1000 patients with documented coronary heart disease will be randomized to either continued treatment with aspirin 160 mg/d or change to clopidogrel 75mg/d. Clinical endpoints will be recorded for at least 2 years and related to the initial aspirin response, assessed by the PFA-100® method, to investigate whether aspirin non-responders have higher composite event rate than responders or whether Clopidogrel treatment in patients non-responsive to aspirin will reduce their risk of future clinical events. The clinical events are the composite of unstable angina, myocardial infarction, stroke or death.

Study Details

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 22, 2005
Enrollment StartApr 1, 2003
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 20.8 years ago

Interventions

aspirindrug

Aspirin 160 mg once daily for two years

clopidogreldrug

clopidogrel 75 mg once daily for two years